ACACIA RESEARCH CORF
Form 10-Q
November 01, 2010

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 10-O

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2010

or

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

95-4405754

(I.R.S. Employer

Identification No.)

FOR THE TRANSITION PERIOD FROM TO

Commission File Number: 0-26068

ACACIA RESEARCH CORPORATION

(Exact name of registrant as specified in its charter)

DELAWARE

(State or other jurisdiction of incorporation or organization) 500 Newport Center Drive, Newport Beach, California 92660

(Address of principal executive offices)

(949) 480-8300

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

x Yes o No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). o Yes o No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act:

Large accelerated filer o

Accelerated filer x

Non-accelerated filer o (Do not check if a smaller reporting company)

Smaller reporting company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

As of October 29, 2010, 34,855,119 shares of the registrant's common stock, \$0.001 par value, were issued and outstanding.

ACACIA RESEARCH CORPORATION

Table Of Contents

Part	T	Financ	ial	Info	rmation
ran	1.	гшанс	lai	11110	ннаион

	Item 1.	Financial Statements	1
		Consolidated Balance Sheets as of September 30, 2010 and December 31, 2009 (Unaudited)	1
		Consolidated Statements of Operations for the Three Months and Nine Months Ended September 30, 2010 and 2009 (Unaudited)	2
		Consolidated Statements of Cash Flows for the Nine Months Ended September 30 2010 and 2009 (Unaudited)	<u>3</u>
		Notes to Consolidated Financial Statements (Unaudited)	4
	Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	<u>12</u>
	Item 3.	Quantitative and Qualitative Disclosures About Market Risk	<u>25</u>
	Item 4.	Controls and Procedures	<u>25</u>
Part II.	Other In	<u>formation</u>	<u>26</u>
	Item 6.	Exhibits	<u>26</u>
Signatur	es		<u>27</u>
Exhibit	Index		<u>28</u>
i			

PART I--FINANCIAL INFORMATION

Item 1. FINANCIAL STATEMENTS

ACACIA RESEARCH CORPORATION AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share information) (Unaudited)

	September 30, 2010	December 31, 2009	
ASSETS			
Current assets:			
Cash and cash equivalents	\$83,426	\$51,735	
Accounts receivable	38,980	5,110	
Prepaid expenses and other current assets	1,779	1,081	
Total current assets	124,185	57,926	
Property and equipment, net of accumulated depreciation	136	163	
Patents, net of accumulated amortization	15,242	17,510	
Investments - noncurrent	2,152	2,152	
Other assets	514	505	
	\$142,229	\$78,256	
LIABILITIES AND STOCKHOLDERS' EQUITY			
Current liabilities:			
Accounts payable and accrued expenses	\$8,367	\$8,006	
Royalties and contingent legal fees payable	24,862	12,402	
Deferred revenues		1,510	
Total current liabilities	33,229	21,918	
Other liabilities	290	369	
Total liabilities	33,519	22,287	
Commitments and contingencies (Note 5)			
Stockholders' equity:			
Preferred stock, par value \$0.001 per share; 10,000,000 shares authorized; no			
shares issued or outstanding	_	_	
Common stock, par value \$0.001 per share; 100,000,000 shares authorized;			
34,762,019 and 31,912,066 shares issued and outstanding as of September 30,	35	32	
2010 and December 31, 2009, respectively			
Additional paid-in capital	186,044	173,672	
Accumulated deficit	(80,921)	(120,242)	
Total Acacia Research Corporation stockholders' equity	105,158	53,462	
Noncontrolling interests in operating subsidiaries	3,552	2,507	
	,	,	

Total stockholders' equity	108,710	55,969
	\$142,229	\$78,256

The accompanying notes are an integral part of these consolidated financial statements.

ACACIA RESEARCH CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except share and per share information) (Unaudited)

(Unaudited)	September 30, September 30,			Nine Months Ended September 30,September 30, 2010 2009		
Revenues	\$63,949	\$ 16,169		\$118,727	\$ 47,482	
Operating costs and expenses: Cost of revenues:						
Inventor royalties	14,508	4,673		21,296	12,069	
Contingent legal fees	9,739	3,799		17,611	10,521	
Litigation and licensing expenses - patents	2,890	3,957		11,019	8,418	
Amortization of patents	1,963	1,245		5,542	3,370	
Marketing, general and administrative expenses (including	g					
non-cash stock compensation expense of \$1,615 and						
\$5,574 for the three and nine months ended September 30		4,709		18,741	15,835	
2010, respectively and \$1,472 and \$5,573 for the three an	d					
nine months ended September 30, 2009, respectively)						
Research, consulting and other expenses - business	461	363		1,286	1,173	
development				•		
Total operating costs and expenses	35,914	18,746	`	75,495	51,386	,
Operating income (loss)	28,035	(2,577)	43,232	(3,904)
Other income:						
Interest income	44	23		83	122	
Gain on foreign currency translation	_				201	
Gain on investments	_	201		_	235	
Total other income	44	224		83	558	
		221		0.5	330	
Income (loss) from operations before provision for incomtaxes	e _{28,079}	(2,353)	43,315	(3,346)
Provision for income taxes	(297) (47)	(605	(124)
Net income (loss) including noncontrolling interests in	27,782	(2.400	`	42,710	(2.470	`
operating subsidiaries	21,102	(2,400)	42,710	(3,470)
Net income attributable to noncontrolling interests in operating subsidiaries	(3,107) (1,029)	(3,389	(3,150)
Net income (loss) attributable to Acacia Research Corporation	\$24,675	\$ (3,429)	\$39,321	\$ (6,620)
Net income (loss) per common share attributable to Acacia Research Corporation:						
Basic income (loss) per share	\$0.75	\$ (0.11)	\$1.24	\$ (0.22)
Diluted income (loss) per share	\$0.73	\$ (0.11)	\$1.14	\$ (0.22)
Weighted average number of shares outstanding, basic	32,794,553	30,071,492	,	31,776,074	29,818,956	,
Weighted average number of shares outstanding, diluted	35,105,353	30,071,492		34,448,666	29,818,956	
6	, - 50,000	,-,-,-,-		, ,	, , _ 10,, 20	

The accompanying notes are an integral part of these consolidated financial statements.

ACACIA RESEARCH CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands) (Unaudited)

	Nine Months Ended			
	September 30, 2010		September 30 2009	0,
Cash flows from operating activities:				
Net income (loss) including noncontrolling interests in operating subsidiaries	\$42,710		\$(3,470)
Adjustments to reconcile net income (loss) including noncontrolling interests in				
operating subsidiaries to net cash provided by operating activities:				
Depreciation and amortization	5,608		3,465	
Non-cash stock compensation	5,574		5,573	
Gain on investments	_		(235)
Changes in assets and liabilities:				
Accounts receivable	(33,870)	901	
Prepaid expenses and other assets	(707)	(4,378)
Accounts payable and accrued expenses	82		2,574	
Royalties and contingent legal fees payable	12,460		1,774	
Deferred revenues	(1,510)	(308)
Net cash provided by operating activities	30,347		5,896	
Cash flows from investing activities:				
Purchase of property and equipment	(39)	(60)
Sale of available-for-sale investments		,	990	,
Patent acquisition costs	(3,074)	(9,162)
- went mequivition costs	(2,07)	,	(3,102	,
Net cash used in investing activities	(3,113)	(8,232)
Cash flows from financing activities:				
Distributions to noncontrolling interests in operating subsidiary	(2,788)	(2,121)
Contributions from noncontrolling interests in operating subsidiary	444			
Repurchased restricted common stock			(1,107)
Proceeds from the exercise of stock options	6,801		85	
Net cash provided by (used in) financing activities	4,457		(3,143)
Increase (decrease) in cash and cash equivalents	31,691		(5,479)
mercuse (accrease) in cush and cush equivalents	51,071		(3,77)	,
Cash and cash equivalents, beginning	51,735		48,279	
Cash and cash equivalents, ending	\$83,426		\$42,800	

The accompanying notes are an integral part of these consolidated financial statements.

ACACIA RESEARCH CORPORATION AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1. DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

Description of Business. As used herein, "Acacia" and the "Company" refer to Acacia Research Corporation and/or its wholly and majority-owned operating subsidiaries. All intellectual property acquisition, development, licensing and enforcement activities are conducted solely by certain of Acacia's wholly and majority-owned operating subsidiaries.

Acacia's operating subsidiaries acquire, develop, license and otherwise enforce patented technologies. Acacia's operating subsidiaries generate revenues and related cash flows from the granting of intellectual property rights for the use of, or pertaining to, patented technologies that such operating subsidiaries own or control. Acacia's operating subsidiaries assist patent owners with the prosecution and development of their patent portfolios, the protection of their patented technologies from unauthorized use, the generation of revenue from users of their patented technologies and, if necessary, the enforcement against unauthorized users of their patented technologies. Currently, on a consolidated basis, Acacia's operating subsidiaries own or control the rights to over 160 patent portfolios, which include U.S. patents and certain foreign counterparts, covering technologies used in a wide variety of industries.

Basis of Presentation. The accompanying consolidated financial statements include the accounts of Acacia and its wholly and majority-owned subsidiaries. Intercompany transactions and balances have been eliminated in consolidation.

Noncontrolling interests in Acacia's majority-owned operating subsidiaries are separately presented as a component of stockholders' equity on the consolidated statements of financial position. Consolidated net income or loss is adjusted to include the net income or loss attributed to the noncontrolling interests in majority-owned operating subsidiaries in the consolidated statements of operations. Refer to accompanying consolidated financial statements for related balances, if any, for the periods presented. There were no net assets attributable to noncontrolling interests at January 1, 2009.

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, certain information and footnotes required by accounting principles generally accepted in the United States of America in annual financial statements have been omitted or condensed in accordance with quarterly reporting requirements of the Securities and Exchange Commission ("SEC"). These interim consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2009, as reported by Acacia in its Annual Report on Form 10-K. The year-end consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America.

The consolidated financial statements of Acacia include all adjustments of a normal recurring nature which, in the opinion of management, are necessary for a fair statement of Acacia's financial position as of September 30, 2010, and results of its operations and its cash flows for the interim periods presented. The results of operations for the three and nine months ended September 30, 2010 are not necessarily indicative of the results to be expected for the entire fiscal year.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Change in Accounting Policy for Term Agreements. Certain revenue agreements provide for the payment of a minimum upfront fee at the inception of each contractual term in consideration for the respective intellectual property

rights granted, hereinafter referred to as "term agreements." Effective October 1, 2009, the Company elected to change its method of accounting for its term agreements to recognize revenue when delivery of the intellectual property rights and all other arrangement deliverables has substantially occurred, which is typically at the time of execution of the related term agreement, or upon receipt of the applicable minimum upfront renewal payment, and when all other revenue recognition criteria, as described below, have been met. Prior to the change in method of accounting, fees for term agreements were deferred and amortized to revenue on a straight-line basis over the applicable contractual term.

ACACIA RESEARCH CORPORATION AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

The effect of the change in accounting policy on Acacia's previously reported consolidated financial statement line items for the three and nine months ended September 30, 2009 was as follows (in thousands, except per share data):

	Three Mon 2009	Three Months Ended September 30, 2009			Nine Months Ended September 30, 2009			
	As Reported	As Adjusted	Effect of Change	As Reported	As Adjusted	Effect of Change		
Revenues	\$12,831	\$16,169	\$3,338	\$40,512	\$47,482	\$6,970		
Inventor royalties	3,010	4,673	1,663	8,890	12,069	3,179		
Contingent legal fees	3,470							